Traws Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate

Traws Pharma posts FY25 net income of $9.2 million; revenue rises to $2.8 million

Traws Pharma Announces up to $60 Million Private Placement Financing

Traws Pharma Inc - Financing Advances Co's Influenza Program Through a Human Challenge Trial for Tivoxavir Marboxil in United Kingdom

Press Release: Traws Pharma Announces Up to $60 Million Private Placement Financing

Traws Pharma Inc - Announces Pricing of Private Placement for 6 Mln Common Shares - SEC Filing

Traws Pharma prices unregistered $10 million PIPE at $1.67 per share

Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement

Traws Pharma delays annual report filing, seeks 15-day extension

Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview

BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold

BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients

Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind

Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16

Traws Pharma initiated with a Buy at Ladenburg

Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza